Dermatol. praxi. 2018;12(2):87-91 | DOI: 10.36290/der.2018.016
Apremilast in dermatology
- Dermatovenerologická klinika FNKV Praha
Current system therapy represents in some cases a compromise between the safety and efficacy of treatment, the route of administration(injection x oral form) and the need for laboratory monitoring during treatment. In particular, the safety of treatmentis an important factor in patients with psoriasis in selecting a particular treatment due to the presence of frequent comorbiditiessuch as diabetes mellitus or cardiovascular disease. Apremilast as a selective PDE4 inhibitor increases cAMP levels and acts specificallyon intracellular signaling, gene and protein expression. It reduces the inflammatory response by reducing the expressionof proinflammatory cytokines TNF-alpha, IL-23, IL-17a, and increasing anti-inflammatory cytokines such as IL-10. In general,there is no influence on specific mediators of the inflammatory process but on restoring the balance of pro-inflammatory andanti-inflammatory signaling pathways (1). Apremilast has an anti-inflammatory, immunomodulatory effect, but does not induceimmunosuppression.
Keywords: apremilast, psoriasis, PDE4
Published: July 1, 2018 Show citation
References
- Salavec M, Krejsek J. Apremilastum nové terapeutikum v léčbě psoriázy. Psoriasis news, 2017; 2: 6-13.
- Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014; 26: 2016-2029.
Go to original source... 
Go to PubMed... - Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013; 12: 888-897 Go to PubMed...
- Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol. 2016; 30: 1942-1950. Go to original source...
- Otezla, SPC, souhrn údajů o přípravku.
- Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br JDermatol. 2015; 173(6): 1387-1399. Go to original source... Go to PubMed...
- AbuHilal M, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study. J Cutan Med Surg. 2016; 20: 313-316 Go to original source... Go to PubMed...
- Crowley J, Diamant Thac¸i D. Long-term safety and tolerability of apremilast in patients with psoriasis:Pooled safety analysis for>156 weeks from 2 phase 3, randomizde, controlled trials (ESTEEM 1 and 2), J AM ACAD Dermatology, Volume 77, Number 2
- Torres T, Puig L, Apremilast: A novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2017.DOI 10.1007/s40257-017-0302-0. Go to original source... Go to PubMed...
- Srbová E. Nová perorání naděje pro pacienty s psoriázou a PsA. AM Review, 2017, number 24, 24-26
- Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015; 73: 37-49. Go to original source... Go to PubMed...